Omics Techniques in Fatty Liver Disease

Universidade Federal do Rio de Janeiro

Status: Not yet enrolling

Conditions: Non-Alcoholic Fatty Liver Disease

Study type: Observational

Funder types: Other

Identifiers

NCT05907408

NASHOmics1

Details and patient eligibility

About

Nonalcoholic steatohepatitis (NASH) is the most common cause of chronic liver disease in Western countries and one of the leading causes of liver transplantation in the world. Its spectrum ranges from simple steatosis to decompensated cirrhosis, resulting from progressive fibrosis due to inflammation and cellular injury. The reasons why patients with the same degree of steatosis have different evolutions are not sufficiently known. The objective of this project is to identify biomarkers that predict disease progression, using omics techniques, which can serve to develop new therapeutic strategies.

Enrollment: 10 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Metabolic syndrome
• Liver steatosis detected on transient hepatic elastography performed in the last 12 months
• Steatosis with or without fibrosis confirmed histologically in a liver biopsy performed in the last 12 months

Exclusion criteria

• Concurrent liver disease (other than NAFLD)
• Chronic or prolonged use of any potential hepatotoxic drug or substance
• HIV infection
• Cancer (except basal cell carcinoma)

Trial design

10 participants in 2 patient groups

Steatosis

Description:

Patients with non-alcoholic fatty liver disease presenting exclusively with steatosis, without fibrosis or inflammation

Steatohepatitis

Description:

Patients with non-alcoholic fatty liver disease presenting with steatosis and degree \>1 of liver fibrosis